Release behavior of cilostazol according to the fabrication methods and ratio of HPMC/PVP

详细信息    查看全文

• 作者：Guk Bin Park (1)
  Hyeon Yoon (1)
  Jung Woo Bae (1)
  Young Un Kim (1)
  Dae Yeon Jeon (1)
  Jeong Eun Song (1)
  Dongwon Lee (1)
  Gilson Khang (1)
  
• 关键词：cilostazol ; hydroxypropyl methylcellulose (HPMC) ; polyvinylpyrrolidone (PVP) ; solid dispersion ; blend
• 刊名：Macromolecular Research
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：21
• 期：9
• 页码：971-976
• 全文大小：1241KB
• 参考文献：1. W. F. Lee and T. M. Tu, / J. Appl. Polym. Sci., 76, 170 (2000). CrossRef
  2. J. Siepmann and N. A. Peppas, / Adv. Drug Deliv. Rev., 48, 139 (2001). CrossRef
  3. E. Karavas, E. Georgarakis, B. Bikiaris, T. Thomas, V. D. Katsos, and A. Xenakis, / Prog. Colloid Polym. Sci., 118, 149 (2001). CrossRef
  4. K. Okimoto, M. Miyake, R. Ibuki, M. Yasumura, N. Ohnishi, and T. Nakai, / Int. J. Pharm., 159, 85 (1997). CrossRef
  5. S. A. Mitchell, T. D. Reynolds, and T. P. Dasbach, / Int. J. Pharm., 250, 3 (2003). CrossRef
  6. S. Itai, M. Nemoto, and S. Kouchiwa, / Chem. Pharm. Bull., 33, 5464 (1985). CrossRef
  7. P. Kleinebudde, / Int. J. Pharm., 96, 119 (1993). CrossRef
  8. H. A. Ravin, A. M. Seligman, and J. Fine, / Engl. J. Med., 247, 921 (1952). CrossRef
  9. S. Sethia and E. Squillante, / Int. J. Pharm., 272, 1 (2004). CrossRef
  10. M. Valero, B. I. Perez Revuelta, and L. J. Rodrigues, / Int. J. Pharm., 253, 97 (2003). CrossRef
  11. L. J. Ford, / Drug Dev. Ind. Pharm., 13, 9 (1987). CrossRef
  12. S. C. Shin, I. J. Oh, and I. B. Koh, / J. Kor. Pharmaceut. Sci., 20, 193 (1990).
  13. P. Mura, A. Manderioli, G. Bramanti, and L. Ceccareli, / Drug Dev. Ind. Pharm., 22, 909 (1996). CrossRef
  14. M. Moneghini, A. Carcano, G. Zingone, and B. Perissutti, / Int. J. Pharm., 175, 177 (1988). CrossRef
  15. A. T. M. Serajuddin, P. C. Sheen, and M. A. Augustine, / J. Pharm. Sci., 77, 414 (1988). CrossRef
  16. R. J. Timkom and N. G. Lord, / J. Pharm. Sci., 68, 601 (1979). CrossRef
  17. H. Akibama, S. Kudo, and T. Shimizu, / Arzneimittelforschung, 35, 1133 (1985).
  18. M. Fujimura, Y. Kamio, M. Saito, T. Hashimoto, and T. Matsuda, / Am. J. Respir. Crit. Care Med., 51, 222 (1995). CrossRef
  19. T. Shimizu, T. Osumi, K. Niimi, and K. Nakagawa, / Arzneimittelforschung, 35, 1117 (1985).
  20. T. Uchikawa, T. Murakami, and H. Furukawa, / Arzneimittelforschung, 42, 322 (1992).
  21. K. Sakuri, T. Maegawa, and T. Takahashi, / Polymer, 41, 7051 (2000). CrossRef
  22. N. Nyamweya and S. W. Hoag, / Pharm. Res., 17, 625 (2000). CrossRef
  23. T. G. Fox, / Bull. Am. Phys. Soc., 1, 123 (1956).
  24. M. Gordon and J. S. Taylor, / J. Appl. Chem., 2, 493 (1952). CrossRef
  25. E. Karavas, E. Georgarakis, and D. Bikiaris, / J. Therm. Anal. Calorim., 84, 125 (2006). CrossRef
  26. G. Van den Mooter, I. Weuts, T. De Ridder, and N. Blaton, / Int. J. Pharm., 316, 1 (2006). CrossRef
  27. K. R. Morris, U. J. Griesser, C. J. Eckhardt, and J. G. Stowell, / Adv. Drug Deliv. Rev., 48, 91 (2001). CrossRef
  
• 作者单位：Guk Bin Park (1)
  Hyeon Yoon (1)
  Jung Woo Bae (1)
  Young Un Kim (1)
  Dae Yeon Jeon (1)
  Jeong Eun Song (1)
  Dongwon Lee (1)
  Gilson Khang (1)
  
  1. Department of BIN Fusion Technology & Department of Polymer Nano Science Technology, Chonbuk National University, Jeonbuk, 561-756, Korea
  
• ISSN：2092-7673

文摘

In this study, we manufactured a polymer blend, using hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP), by spray drying method to improve the characteristics of polymers. This polymer blend was used to improve the drug delivery of cilostazol, a phosphodiesterase inhibitor that decreases serum triglycerides, is a direct arterial vasodilator, and inhibits platelet aggregation and smooth muscle cell proliferation. Compatibility with this drug was achieved when the polymer blend of HPMC and PVP were spray dried. Various ratios of the two ingredients were blended to determine optimum release rate of this poorly soluble drug. Cilostazol blended with different ratios of HPMC and PVP was analyzed by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) to confirm surface morphology and combination of drug and polymer. Differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR) were conducted to confirm thermodynamic properties and chemical structure change, respectively. Change in the drug release of cilostazol was expected by adjusting the HPMC and PVP blend ratio in gastric juice (pH 1.2).